The first day of autumn is always a little bittersweet: it signals the end of the long days of summer and vacations, but there’s also excitement about the new season and a fresh start. Of course the work never stops for an organization like CARRA, but the Fall season is again bringing many exciting changes! It’s clear that Arthritis Foundation support continues to be critical to the progress that we’ve made since our partnership began in 2015.
Here’s what we are expecting for CARRA in the last quarter of 2017:
- The 4,000th enrolled patient in the CARRA Registry
- Enrolling the first patients with JDM and scleroderma in the CARRA Registry
- Activation of up to 10 new CARRA Registry sites (total number going up to 70 sites)
- Activation of our first non-North American registry site at Tel Aviv University in Israel
- Launch of a small pilot program to support research coordinator start up at a few sites (more details and call for applications available shortly)
- Activation of the new CARRA Scientific Review Committee (led by Terry Moore)
- 2nd 2017 cycle of Small Grants and the 2017 Large Grants to be awarded
- Launch of the CARRA Ethics and Conflict of Interest Committee
- Launch of the NICHD PROMOTE grant (Mara Becker and Sue Thompson, co-PIs) to study methotrexate pharmacogenetics in CARRA Registry participants
Registration Deadline: Monday, October 30, 2017
Date: November 6, 2017 (Monday)
Time: 6:30-7:30 (CARRA Meeting)
7:30-10:00 PM (CARRA-AF Reception)
Location: Hard Rock Hotel-San Diego
207 Fifth Ave.
San Diego, CA 92101
Who may attend? Both the CARRA Meeting and CARRA-AF Reception are open to all ACR Meeting attendees. You must register to attend each event.
CARRA invites you to attend our annual meeting during the ACR conference! We will hold a one hour meeting at the Hard Rock Hotel to provide attendees with brief updates from CARRA and the Arthritis Foundation, followed by an interactive panel presentation and discussion with our current CARRA interns.
Date: Monday, November 6, 2017
Time: 6:30 PM - 7:30 PM
CARRA is excited to be co-hosting this year's reception at the ACR Conference with the Arthritis Foundation. Please join us for drinks and h'ors d'oeuvres immediately following the CARRA meeting.
Date: Monday, November 6, 2017
Time: 7:30 PM - 10:00 PM
Registration deadline: Monday, October 30, 2017
Registry Update October 13, 2017
CARRA Registry: 4,058
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), Inc. announced today that the first two patients had enrolled in the Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis (STOP-JIA) project. STOP-JIA aims to answer a critical question facing patients and doctors: “When is the best time to start biologic medications in polyarticular JIA?”
All CARRA-related publications and presentations which include results derived from data and bio specimens collected via the CARRA Registry protocols and sub-studies as well as surveys and other publications related to the use of CARRA infrastructure for mailing lists, conference time, and funding are subject to the CARRA Publication and Presentation Guidelines.
In order to expedite the review process, we have set up an online form for submitting your materials for review.
This form must be used to submit papers/manuscripts, abstracts, meeting proceedings, posters, press releases, and slides for review by the Publications committee.
If you have any questions about the publication review process, please contact CARRA Director of Administration, Brian Mondragón Jones ([email protected]).
What Caught My Eye: Trauma and SLE: Continuing the Discussion on a link between Adverse Experiences and Autoimmune Disease
Tamar Rubinstein, MD
Children's Hospital at Montefiore
Back in July, Jim Jarvis wrote in “What Caught Our Eye” about an association between Adverse Childhood Experiences (ACEs) and autoimmune disease. He pointed out that over the past decade, evidence has amassed linking ACEs (which include trauma, neglect, parental incarceration, food insecurity, and racial discrimination) to poor health and the development of chronic disease. This association is observed across cultures and people that have differed by geography, ethnicity, and even era of time. Many studies have noted a dose response, where more cumulative experiences lead to increasing risk of disease. And as Jim pointed out a few months ago, autoimmune diseases appear to follow the same pattern.